NCT02836418View on ClinicalTrials.gov

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 13, 2016

Primary Completion Date

April 18, 2017

Study Completion Date

April 18, 2017

Conditions
Facioscapulohumeral Muscular DystrophyLimb Girdle Muscular Dystrophy
Interventions
DRUG

ATYR1940

Concentrate for solution for infusion

Trial Locations (5)

20133

Foundation IRCCS Neurological Institute Carlo, Milan

84132

University of Utah, Salt Lake City

92697

University of California, Irvine, ALS and Neuromuscular Center, Irvine

94305

Stanford University, Stanford

Unknown

Rigshospitalet, University of Copenhagen, Copenhagen

All Listed Sponsors
lead

aTyr Pharma, Inc.

INDUSTRY

NCT02836418 - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) | Biotech Hunter | Biotech Hunter